SCHEMBL5653199

SCHEMBL5653199

COC(=O)c1ccc(CCNC(=O)[C@H](CCCN)NC(=O)c2cc3ccccc3o2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGER4 P35408 3/20 0.52
NAMPT P43490 1/20 0.50
TAS1R3 Q7RTX0 3/20 0.49
TAS1R1 Q7RTX1 3/20 0.49
MCHR1 Q99705 1/20 0.48
MMP8 P22894 1/20 0.48
KDM4E B2RXH2 1/20 0.47
MEN1 O00255 4/20 0.47
KMT2A Q03164 4/20 0.47
NPC1 O15118 3/20 0.46
RAB9A P51151 3/20 0.46
CTSL P07711 1/20 0.45
CTSS P25774 1/20 0.45
CTSK P43235 1/20 0.45
MAPT P10636 2/20 0.44
TSHR P16473 2/20 0.44
MAPK1 P28482 1/20 0.44
CASP3 P42574 1/20 0.44
HSD17B10 Q99714 1/20 0.44
SENP7 Q9BQF6 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5654830 0.93 PTGER4 (0.56) PTGER4NAMPTTAS1R3TAS1R1MCHR1
SCHEMBL5651439 0.88 PTGER4 (0.58) PTGER4NAMPTTAS1R3TAS1R1MCHR1
SCHEMBL5653336 0.88 PTGER4 (0.55) PTGER4NAMPTTAS1R3TAS1R1MCHR1
SCHEMBL5668471 0.88 PTGER4 (0.55) PTGER4NAMPTTAS1R3TAS1R1MCHR1
SCHEMBL5668462 0.88 PTGER4 (0.55) PTGER4NAMPTTAS1R3TAS1R1MCHR1
SCHEMBL5653684 0.87 PTGER4 (0.72) PTGER4NAMPTTAS1R3TAS1R1MCHR1
SCHEMBL5657127 0.87 PTGER4 (0.58) PTGER4NAMPTTAS1R3TAS1R1MCHR1
SCHEMBL5652845 0.84 PTGER4 (0.59) PTGER4NAMPTTAS1R3TAS1R1MCHR1
SCHEMBL5654281 0.83 PTGER4 (0.59) PTGER4NAMPTMCHR1MMP8MEN1
SCHEMBL5653187 0.80 PTGER4 (0.71) PTGER4NAMPTTAS1R3TAS1R1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070142638-A1 Ornithine derivatives as prostaglandin e2 agonists or antagonists ASTELLAS PHARMA INC. (JP) 2007-06-21 US disclosed
EP-1697337-A2 ORNITHINE DERIVATIVES AS PROSTAGLANDIN-E2-AGONISTS OR ANTAGONISTS Astellas Pharma Inc. (JP) 2006-09-06 EP disclosed
WO-2005061475-A2 ORNITHINE DERIVATIVES AS PROSTAGLANDIN E2 AGONISTS OR ANTAGONISTS ASTELLAS PHARMA INC. (JP) 2005-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142638-A1 Ornithine derivatives as prostaglandin e2 agonists or antagonists PTGER4, OXER1, RXFP4 PTGER4 1/4885NAMPT 2692/4885TAS1R3 2373/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.